Novel biomarker analysis predicting efficacy of immune checkpoint inhibitors

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10687
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Fukushima Medical University
• Principal Investigator: SUZUKI HIROYUKI 福島県立医科大学, 医学部, 教授 (30322340)
• Research Collaborator: SHIO yutaka ; HASEGAWA takeo ; OKABE naoyuki ; MUTO satoshi ; HUKUHARA mitsuro ; YAMAURA takumi ; OZAKI yuki (OWADA yuki) ; WATANABE masayuki ; TAKAGI hironori
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: がん免疫 / 免疫療法 / 免疫チェックポイント阻害薬 / バイオマーカー

Outline of Final Research Achievements

We analyzed whole exome sequencing for over 200 cases of patients with non-small cell lung cancer specimen by using next generation sequencing technique to look at the predictive biomarkers for immune checkpoint inhibitors. And relationship among tumor mutation burden, PD-L1 expression, tumor infiltrating lymphocytes and several specific gene alterations were studied. We found no clear correlations among those parameters, therefor we proposed combination analysis by using those parameters. Furthermore, we found the novel findings that the amount of tumor mutation burden strongly correlated with prognosis of patinets with non small cell lung cancer.

Free Research Field

呼吸器外科

Academic Significance and Societal Importance of the Research Achievements

免疫チェックポイント阻害薬のバイオマーカーの抽出は症例の選択や医療経済的にも重要な課題である．今回の我々の検討結果の意義は単独では十分ではない個々のパラメータを複合的に解析することでより効果的なバイオマーカーとなることを明らかにした点にある．さらに，腫瘍の遺伝子変異数が肺癌の予後に関連するという結果は今後拡大されるであろう周術期での免疫チェックポイント阻害薬の治療選択を考慮するうえで，重要な基礎的知見となるものと考えている．